Cancer Screening
is a right not a privilege.

With a new approach to VOC biomarkers,
EARLY will revolutionize the way cancer
is detected and treated.

Cancer Screening
is a right not a privilege.

With a new approach to VOC biomarkers, EARLY will revolutionize the way cancer is detected and treated.

 Our novel proprietary multi-cancer screening platform will make cancer screening

ACCURATE

ACCESSIBLE

AFFORDABLE

ACCEPTABLE

 and create value for all stakeholders,
across the screening and treatment pipeline: 

Our novel proprietary multi-cancer screening
platform will make cancer screening:

ACCURATE

ACCESSIBLE

AFFORDABLE

ACCEPTABLE

and create value for all stakeholders,
across the screening and treatment pipeline: 

PATIENTS

  • Safe & convenient way to take control over their health

  • Increase chances of survival

  • Improve quality of life 

PAYERS

  • Reduce diagnostic and treatment costs 

POLICY MAKERS

  • Remove barriers for screening

  • Reduce geographical and economic disparities

  • Increase participation and adherence 

PROVIDERS

  • Remove system barriers

  • Increase efficiency

PATIENTS

  • Safe & convenient way to take control over their health

  • Increase chances of survival

  • Improve quality of life 

PAYERS

  • Reduce diagnostic and treatment costs 

POLICY MAKERS

  • Remove barriers for screening

  • Reduce geographical and economic disparities

  • Increase participation and adherence 

PROVIDERS

  • Remove system barriers

  • Increase efficiency

PATIENTS

  • Safe & convenient way to take control over their health

  • Increase chances of survival

  • Improve quality of life 

PAYERS

  • Reduce diagnostic and treatment costs 

POLICY MAKERS

  • Remove barriers for screening

  • Reduce geographical and economic disparities

  • Increase participation and adherence 

PROVIDERS

  • Remove system barriers

  • Increase efficiency

EARLY’s Platform Benefits

SAFE

ACCURATE

SIMPLE

MULTI-CANCER

AFFORDABLE

Scientific
Approach

It has been well known to science for many years that tumors secrete materials (Volatile Organic Compounds – VOCs) into a person’s bloodstream, urine, and other body secretion. This generally happens from the earliest days of the tumor’s formation. 

These materials have distinct odors which are available for diagnostic testing. Many techniques to detect these molecular markers of cancer are being explored, but none have matured into a working, scalable, screening test. 

At EARLY, we created a novel multi-cancer screening platform, the Biosensor Platform (BSP) Urine Test, to make cancer screening accurate, safe, non-invasive, simple, cost effective and accessible to people around the world, starting with lung cancer. 

With a single urine test, EARLY’s platform will be able to detect cancer from its very early stages, allow for more treatment options and dramatically increase patients’ survival rates and quality of life.
 

Scientific
Approach

It has been well known to science for many years that tumors secrete materials (Volatile Organic Compounds – VOCs) into a person’s bloodstream, urine, and other body secretion. This generally happens from the earliest days of the tumor’s formation. 

These materials have distinct odors which are available for diagnostic testing. Many techniques to detect these molecular markers of cancer are being explored, but none have matured into a working, scalable, screening test. 

 
 

At EARLY, we created a novel multi-cancer screening platform, the Biosensor Platform (BSP) Urine Test, to make cancer screening accurate, safe, non-invasive, simple, cost effective and accessible to people around the world, starting with lung cancer. 

With a single urine test, EARLY’s platform will be able to detect cancer from its very early stages, allow for more treatment options and dramatically increase patients’ survival rates and quality of life.

Scientific
Approach

It has been well known to science for many years that tumors secrete materials (Volatile Organic Compounds – VOCs) into a person’s bloodstream, urine, and other body secretion. This generally happens from the earliest days of the tumor’s formation. 

These materials have distinct odors which are available for diagnostic testing. Many techniques to detect these molecular markers of cancer are being explored, but none have matured into a working, scalable, screening test. 

 
 

At EARLY, we created a novel multi-cancer screening platform, the Biosensor Platform (BSP) Urine Test, to make cancer screening accurate, safe, non-invasive, simple, cost effective and accessible to people around the world, starting with lung cancer. 

With a single urine test, EARLY’s platform will be able to detect cancer from its very early stages, allow for more treatment options and dramatically increase patients’ survival rates and quality of life.

About
EARLY

EARLY is the world’s pioneer provider of VM (Volatile Markers) test for early detection of cancer. 

The key to fighting cancer is early detection, meaning finding the disease when it is still curable. Our test is specially designed to meet the needs and demands of large-scale population/targeted screening programs, by being acceptable, affordable and accessible. 

With a simple, safe, highly sensitive, inexpensive urine test, EARLY’s proprietary evidence-based novel platform will enable diagnostic level testing on a population screening scale. 

 

The company’s test will revolutionize the way cancer is detected, starting with lung cancer, and dramatically reduce the disease’s global human and financial burden.

In the future, the same technology will be modified to allow detection of other cancer types, creating a unique multi-cancer screening platform.

About
EARLY

EARLY is the world’s pioneer provider of VM (Volatile Markers) test for early detection of cancer. 

The key to fighting cancer is early detection, meaning finding the disease when it is still curable. Our test is specially designed to meet the needs and demands of large-scale population/targeted screening programs, by being acceptable, affordable and accessible. 

With a simple, safe, highly sensitive, inexpensive urine test, EARLY’s proprietary evidence-based novel platform will enable diagnostic level testing on a population screening scale. 

 

The company’s test will revolutionize the way cancer is detected, starting with lung cancer, and dramatically reduce the disease’s global human and financial burden.

In the future, the same technology will be modified to allow detection of other cancer types, creating a unique multi-cancer screening platform.

About
EARLY

EARLY is the world’s pioneer provider of VM (Volatile Markers) test for early detection of cancer. 

The key to fighting cancer is early detection, meaning finding the disease when it is still curable. Our test is specially designed to meet the needs and demands of large-scale population/targeted screening programs, by being acceptable, affordable and accessible. 

With a simple, safe, highly sensitive, inexpensive urine test, EARLY’s proprietary evidence-based novel platform will enable diagnostic level testing on a population screening scale. 

 

Research Partners

Research Partners

Leadership Team

Our team comprise of highly experienced multidisciplinary experts in the fields of Biology, Zoology, Engineering, Bioinformatics and Marketing. 

Michal Mark Danieli, PhD

CEO

PhD in Cell Biology & Immunology.
Ex-senior researcher at Sheba.
Founded several startups in the health-cancer space.

Avichay
Porat

COO

Co-Founder in several software & IOT start-up companies.
Extensive track record leading business and operation activities.

Adi Laser, PhD

Lab Director

PhD in Cell & Molecular Biology with expertise in cancer and neurodegenerative diseases.
Experienced lab manager and team leader.

Israel Alva

Lead Zoologist

Animal behavior expert. Over 25 years of experience in training animals for operational tasks. Served over 20 years in Israeli Navy Seals in a special R&D unit. B.Sc. in Behavioral Science from Ben Gurion University

Michael Kolomenkin, PhD

Data Scientist

PhD in Electrical and Electronics engineering, over a decade of hands-on and leadership experience in data science and machine learning, building systems from POC to production.

Advisory Board

David M. Knapp,
PhD

12 years VP R&D in Boston Scientific. Led PI Vascular R&D portfolio driving revenue growth in a $1B+ division of BSC. Board member of several research institutes and life science companies. 

Elad Duschak

Over 20 years of international experience in senior leadership roles in business development, strategy and general management within the healthcare industry

Neal Navani,
M.B.B.S.

Lead clinician for the lung cancer services at UCLH, senior clinical lead of the UK National Lung Cancer Audit , Respiratory representative on the  NICE lung cancer guideline. Chairs the lung cancer board for the North Central and East London Cancer Alliance.

Ory Wiesel,
MD

Thoracic and Esophageal Surgery expert.
Innovation leader in diagnosis and treatment of lung cancer.

Sook-Whan Sung,
MD

Thoracic surgical oncology expert, with over 20 years of experience leading pulmonary research in several medical centers.

Contact Us

Subscription Form

Contact Us

Subscription Form

Contact Us

Subscription Form

News & Updates

News & Updates

Early in Channel 12 News
English subs

Channel 12
29.01.2023

Israeli scientists who have trained rats to sniff out lung cancer from human urine claim the rodents are 90 per cent accurate... and now they want to do a clinical trial in the UK

Daily Mail
08.05.2023

A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection

MDPI
08.06.2023
We are super excited and proud to share that the scientific article “A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection” was published by the highly renowned Biosensors MDPI scientific journal! This article, a fruit of a joint study with leading Surgical and Oncology Lung Cancer experts, is yet another validation from the international scientific community of EARLY’s groundbreaking technology. The future, where early detection of different types of cancer can be done at home using a simple urine test – has never been closer.
Please do get in touch if you would like to learn more about EARLY.

Thank you Calcalist and Poalim-Tech for picking EARLY as one of 18 startups (out of 220 who applied) to pitch at the RoadShow+ event. Top-notch VCs, and good seeds sown....

19.12.2023

Proud to be among the few Israeli biotech startups selected for the prestigious Healthtech Hub in Boston

Funded by HHS, and Operated by the Israeli American Chamber of Commerce, Mass General Hospital, and ARMI, 6 selected Israeli startup participated in an amazing 3 week program, meeting with clinical leaders and business field experts all in the purpose accelerating new and promising Israeli technologies into the US market. 

10.08.2023

A joint research agreement in the field of early lung cancer detection using EARLY's technology has been signed with Memorial Sloan Kettering Cancer Center in NYC. A major milestone on EARLY's path to the US market.

11.07.2023

A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection

We are super excited and proud to share that the scientific article “A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection” was published by the highly renowned Biosensors MDPI scientific journal! This article, a fruit of a joint study with leading Surgical and Oncology Lung Cancer experts, is yet another validation from the international scientific community of EARLY’s groundbreaking technology. The future, where early detection of different types of cancer can be done at home using a simple urine test – has never been closer.
Please do get in touch if you would like to learn more about EARLY.

MDPI
08.06.2023

Israeli scientists who have trained rats to sniff out lung cancer from human urine claim the rodents are 90 per cent accurate... and now they want to do a clinical trial in the UK

Daily Mail
08.05.2023

Early in Channel 12 News
English subs

Channel 12
29.01.2023

Early in Channel 12 News
English subs

Channel 12
29.01.2023

Israeli scientists who have trained rats to sniff out lung cancer from human urine claim the rodents are 90 per cent accurate... and now they want to do a clinical trial in the UK

Daily Mail
08.05.2023

A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection

MDPI
08.06.2023
We are super excited and proud to share that the scientific article “A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection” was published by the highly renowned Biosensors MDPI scientific journal! This article, a fruit of a joint study with leading Surgical and Oncology Lung Cancer experts, is yet another validation from the international scientific community of EARLY’s groundbreaking technology. The future, where early detection of different types of cancer can be done at home using a simple urine test – has never been closer.
Please do get in touch if you would like to learn more about EARLY.